Interaction Between VLDL and Phosphatidylcholine Liposomes Generates New γ-LpE-like Particles
Tóm tắt
One of the subfractions of HDL involved in reverse cholesterol transport is γ-LpE. It has been assumed that, like preβ-LpAI, it can be generated during the interaction between phosphatidylcholine liposomes and lipoproteins and can contribute to more efficient cholesterol efflux after the introduction of liposomes to plasma. However, there has been no evidence concerning what the sources of these particles in plasma might be. Here, we determined whether the interaction of phosphatidylcholine liposomes with VLDL and the subsequent conversions of particles could be a source of new γ-LpE particles. We found that the interaction between liposomes and VLDL affected its lipid and protein composition. The content of phospholipids increased (~96 %) while the content of free cholesterol and apolipoprotein E decreased in VLDL during the reaction with liposomes (~100 and ~24 %, respectively). New particles which did not contain apolipoprotein B were generated. Heterogeneous HDL-sized populations of particles were generated, containing phospholipids and apolipoprotein E as the sole apolipoprotein, with densities from 1.063 to 1.21 g/ml, either with γ-mobility on agarose gel and Stokes diameters from 8.58 to 22.07 nm or with preβ-mobility and Stokes diameters from 9.9 to 21.08 nm. The obtained results contribute to the understanding of changes in lipoproteins under the influence of phosphatidylcholine liposomes, showing the formation of new (γ-LpE)-like and (preβ-LpE)-like particles, similar in mobility and size to plasma HDL-LpE. These newly generated particles can claim a share of the antiatherogenic effects of liposomes, observed in studies both in vitro and in vivo.
Tài liệu tham khảo
Faxon DP, Creager MA, Smith SC Jr, Pasternak RC, Olin JW, Bettmann MA, Criqui MH, Milani RV, Loscalzo J, Kaufman JA, Jones DW, Pearce WH (2004) Atherosclerotic Vascular Disease Conference: executive summary: Atherosclerotic Vascular Disease Conference proceedings for healthcare professionals from a Special Writing Group of the American Heart Association. Circulation 109(21):2595–2604
Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145(3):341–355
Cuchel M, Rader DJ (2006) Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113(21):2548–2555
Rader DJ (2003) Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 92(4a):42j–49j
Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Philips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125(15):1905–1919
Mahley RW, Huang Y, Weisgraber KH (2006) Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 116(5):1226–1229
Greenow K, Pearce NJ, Ramji DP (2005) The key role of apolipoprotein E in atherosclerosis. J Mol Med 83(5):329–342
Lund-Katz S, Phillips MC (2010) High density lipoprotein structure–function and role in reverse cholesterol transport. Subcell Biochem 51:183–227
Krimbou L, Marcil M, Chiba H, Genest J Jr (2003) Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles. J Lipid Res 44(5):884–892
Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G (1994) A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci 91(5):1834–1838
Huang Y, von Eckardstein A, Wu S, Assmann G (1995) Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest 96(6):2693–2701
von Eckardstein A, Huang Y, Wu S, Funke H, Noseda G, Assmann G (1995) Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol 15(5):691–703
von Eckardstein A, Jauhiainen M, Huang Y, Metso J, Langer C, Pussinen P, Wu S, Ehnholm C, Assmann G (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates preβ1-HDL. Biochim Biophys Acta 1301(3):255–262
von Eckardstein A, Huang Y, Wu S, Sarmadi AS, Schwarz S, Steinmetz A, Assmann G (1995) Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol 15(10):1755–1763
Krimbou L, Tremblay M, Jacques H, Davignon J, Cohn JS (1998) In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma. J Lipid Res 39(4):861–872
Hannuksela ML, Brousseau ME, Meyn SM, Nazih H, Bader G, Shamburek RD, Alaupovic P, Brewer HB Jr (2002) In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II. Atherosclerosis 165(2):205–220
Hajj Hassan H, Blain S, Boucher B, Denis M, Krimbou L, Genest J (2005) Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release. J Lipid Res 46(7):1457–1465
Rodrigueza WV, Williams KJ, Rothblat GH, Phillips MC (1997) Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler Thromb Vasc Biol 17(2):383–393
Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ (1998) Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta 1368(2):306–320
Cho BH, Park JR, Nakamura MT, Odintsov BM, Wallig MA, Chung BH (2010) Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits. Exp Biol Med 235(10):1194–1203
Jian B, de la Llera-Moya M, Royer L, Rothblat G, Francone O, Swaney JB (1997) Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res 38(4):734–744
Chung BH, Franklin F, Liang P, Doran S, Cho BH, Curcio CA (2005) Phosphatidylcholine-rich acceptors, but not native HDL or its apolipoproteins, mobilize cholesterol from cholesterol-rich insoluble components of human atherosclerotic plaques. Biochim Biophys Acta 1733(1):76–89
Williams KJ, Phillips MC, Rodrigueza WV (1998) Structural and metabolic consequences of liposome–lipoprotein interactions. Adv Drug Deliv Rev 32(1–2):31–43
Pownall HJ, Ehnholm C (2005) Enhancing reverse cholesterol transport: the case for phosphatidylcholine therapy. Curr Opin Lipidol 16(3):265–268
Tall AR (1980) Studies on the transfer of phosphatidylcholine from unilamellar vesicles into plasma high density lipoproteins in the rat. J Lipid Res 21(3):354–363
Tall AR, Green PH (1981) Incorporation of phosphatidylcholine into spherical and discoidal lipoproteins during incubation of egg phosphatidylcholine vesicles with isolated high density lipoproteins or with plasma. J Biol Chem 256(4):2035–2044
Wroblewska M, Czyzewska M, Wolska A, Kortas-Stempak B, Szutowicz A (2010) Apo A-II participates in HDL-liposome interaction by the formation of new pre-β mobility particles and the modification of liposomes. Biochim Biophys Acta 1801(12):1323–1329
Wroblewska M, Kortas-Stempak B, Szutowicz A, Badzio T (2009) Phospholipids mediated conversion of HDLs generates specific apoA-II pre-β mobility particles. J Lipid Res 50(4):667–675
Williams KJ, Tall AR, Bisgaier C, Brocia R (1987) Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. J Clin Invest 79(5):1466–1472
Guo LS, Hamilton RL, Goerke J, Weinstein JN, Havel RJ (1980) Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. J Lipid Res 21(8):993–1003
McEneny J, Loughrey CM, McNamee PT, Trimble ER, Young IS (1997) Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 129(2):215–220
Guha M, England C, Herscovitz H, Gursky O (2007) Thermal transitions in human very-low-density lipoprotein: fusion, rupture, and dissociation of HDL-like particles. Biochemistry 46(20):6043–6049
Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80(5):2418–2428
Bates SR, Coughlin BA, Mazzone T, Borensztajn J, Getz GS (1987) Apoprotein E mediates the interaction of beta-VLDL with macrophages. J Lipid Res 28(7):787–797
Mendez AJ, He JL, Huang HS, Wen SR, Hsia SL (1988) Interaction of rabbit lipoproteins and red blood cells with liposomes of egg yolk phospholipids. Lipids 23(10):961–967
Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ (1985) Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 26(7):842–851
Peters-Libeu CA, Newhouse Y, Hall SC, Witkowska HE, Weisgraber KH (2007) Apolipoprotein E•dipalmitoylphosphatidylcholine particles are ellipsoidal in solution. J Lipid Res 48(5):1035–1044
Garai K, Baban B, Frieden C (2011) Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles. Biochemistry 50(13):2550–2558
Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M (1995) Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1254(1):77–88
Packard CJ, Shepherd J (1997) Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17(12):3542–3556
Barbagallo CM, Rizzo M, Noto D, Frasheri A, Pernice V, Rubino A, Pieri D, Pinto V, Cefalu AB, Giordano C, Notarbartolo A, Averna MR (2006) Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. Metabolism 55(5):662–668
Genest JJ Jr, Bard JM, Fruchart JC, Ordovas JM, Wilson PF, Schaefer EJ (1991) Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 90(2–3):149–157
Cohn JS, Tremblay M, Batal R, Jacques H, Veilleux L, Rodriguez C, Barrett PH, Dubreuil D, Roy M, Bernier L, Mamer O, Davignon J (2002) Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia. J Lipid Res 43(9):1464–1471
Ooi EM, Ng TW, Watts GF, Chan DC, Barrett PH (2012) Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. J Lipid Res 53(11):2443–2449
Krimbou L, Denis M, Haidar B, Carrier M, Marcil M, Genest J Jr (2004) Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res 45:839–848